光子与质子大分割放疗在前列腺癌中的比较:系统综述与荟萃分析
该系统综述与荟萃分析检索至2022年4月,比较质子治疗(PT)与光子放疗(XRT)大分割根治性放疗在前列腺癌中的毒性与疗效,共纳入160项研究;PT组≥2级急性胃肠道毒性发生率显著更低(2% vs 7%),5年生化无复发生存率更高(95% vs 91%),其他结局无统计学显著差异。
要点
- PT组≥2级急性胃肠道毒性发生率为2%,XRT组为7%。
- PT组5年生化无复发生存率为95%,XRT组为91%。
- 中度大分割亚组及中危、低危患者中PT的5年b-RFS获益仍存在。
核心结论
- 本研究表明PT用于局限性前列腺癌治疗安全有效,但需要更多随机对照试验数据以得出可靠证据,并需进一步努力识别最可能从PT获益的患者亚组。
研究设计与样本
- 系统检索PubMed、Embase和Cochrane Library数据库至2022年4月,纳入接受根治性大分割放疗(PT或XRT)的前列腺癌患者,共230项研究符合纳入标准,因人群重叠最终纳入160项研究进行分析。
主要发现
- PT组≥2级急性胃肠道毒性发生率显著低于XRT组(2% vs 7%)。
- PT组5年生化无复发生存率显著高于XRT组(95% vs 91%)。
- PT在5年生化无复发生存方面的获益在中度大分割亚组中仍存在(P=0.0122)。
- PT在5年生化无复发生存方面的获益在中危和低危患者中仍存在(P值分别<0.0001和0.0368)。
- 其他考虑结局未见统计学相关差异。
关键数值与推荐
- 主要结局为≥2级急性和晚期泌尿生殖系统或胃肠道毒性风险。
- 次要结局为5年生化无复发生存、临床无复发生存、无远处转移生存和前列腺癌特异性生存。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要更多随机对照试验数据以在该背景下得出可靠证据。
- 需进一步努力识别最可能从PT获益的患者亚组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High-level evidence on hypofractionated proton therapy (PT) for localized and locally advanced prostate cancer (PCa) patients is currently missing. The aim of this study is to provide a systematic literature review to compare the toxicity and effectiveness of curative radiotherapy with photon therapy (XRT) or PT in PCa. METHODS: PubMed, Embase, and the Cochrane Library databases were systematically searched up to April 2022. Men with a diagnosis of PCa who underwent curative hypofractionated RT treatment (PT or XRT) were included. Risk of grade (G) ≥ 2 acute and late genitourinary (GU) OR gastrointestinal (GI) toxicity were the primary outcomes of interest. Secondary outcomes were five-year biochemical relapse-free survival (b-RFS), clinical relapse-free, distant metastasis-free, and prostate cancer-specific survival. Heterogeneity between study-specific estimates was assessed using Chi-square statistics and measured with the I2 index (heterogeneity measure across studies). RESULTS: A total of 230 studies matched inclusion criteria and, due to overlapped populations, 160 were included in the present analysis. Significant lower rates of G ≥ 2 acute GI incidence (2 % vs 7 %) and improved 5-year biochemical relapse-free survival (95 % vs 91 %) were observed in the PT arm compared to XRT. PT benefits in 5-year biochemical relapse-free survival were maintained for the moderate hypofractionated arm (p-value 0.0122) and among patients in intermediate and low-risk classes (p-values < 0.0001 and 0.0368, respectively). No statistically relevant differences were found for the other considered outcomes. CONCLUSION: The present study supports that PT is safe and effective for localized PCa treatment, however, more data from RCTs are needed to draw solid evidence in this setting and further effort must be made to identify the patient subgroups that could benefit the most from PT.
引用
- Corrao G, Marvaso G, Mastroleo F, et al. Photon vs proton hypofractionation in prostate cancer: A systematic review and meta-analysis. Radiother Oncol. 2024. PMID: 38561122. doi:10.1016/j.radonc.2024.110264
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。